1. Home
  2. NEWS
  3. FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy

Porosome Therapeutics, Inc. enters a new frontier in secretory defect therapeutics through porosome reconstitution

BOSTON--()--Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

https://www.businesswire.com/news/home/20250225004448/en/FDA-Grants-Orphan-Drug-Designation-to-Revolutionary-Cystic-Fibrosis-Therapy

Forbes Magazine Features Professor Bhanu Jena
Prof. Bhanu P. Jena to present the first Plenary Keynote Lecture entitled "Development of a New Class of AI-Engineered Porosome Medicines" at the Bio Week Boston on September 24th 2026 being held at the Hynes Convention Center, Boston. Over 5000 attendees from 48 countries will be participating.
Porosome Therapeutics Chairman Prof. Bhanu P. Jena is Co-Chair in the World Congress in Nanomedicine being held in New Delhi (September 27 - 30th, 2026) and Chaired by Prof. Roger D. Kornberg, 2006 Nobel Laureate in Chemistry.